Atrium Therapeutics Doses First Patient in Phase 1/2 Trial of ATR 1072

10:04 AM EDT, 10/27/2026 (MT Newswires) -- Atrium Therapeutics (RNA) said Tuesday it has dosed the first patient in the phase 1/2 Corventis trial of ATR 1072, its lead experimental therapy for PRKAG2 syndrome. The company expects initial proof-of-concept data from the study in H2 2027, it said. PRKAG2 syndrome is a rare inherited heart muscle disease with no approved treatments, and ATR 1072 is designed to silence the faulty PRKAG2 gene to reduce glycogen buildup in the heart, the company said. Shares of the company were up 2.2% in Tuesday trading. Price: 8.23, Change: +0.18, Percent Change: +2.24